Literature DB >> 33884579

Comparison of the cost in percutaneous coronary intervention between ST-segment elevation myocardial infarction vs. non-ST-segment elevation myocardial infarction.

Tsukasa Murakami1, Kenichi Sakakura2, Yousuke Taniguchi1, Kei Yamamoto1, Takunori Tsukui1, Masaru Seguchi1, Hiroyuki Jinnouchi1, Hiroshi Wada1, Hideo Fujita1.   

Abstract

Percutaneous coronary intervention (PCI) is a standard strategy for non-ST-segment elevation myocardial infarction (NSTEMI) as well as for ST-segment elevation myocardial infarction (STEMI). The device cost for PCI may be more expensive in NSTEMI, because the culprit lesion morphology may be more complex in NSTEMI. This study aimed to compare the total device cost of PCI between STEMI and NSTEMI. We included 504 patients with acute myocardial infraction (AMI) who underwent PCI, and divided those into a STEMI group (n = 286) and a NSTEMI group (n = 218). We compared the total device cost, the number of used devices, and procedure cost between the 2 groups. The total device cost was significantly higher in the NSTEMI group [¥371,300 (¥320,700-503,350)] than in the STEMI group [¥341,200 (¥314,200-410,475)] (p = 0.001), whereas the procedure cost was significantly higher in the STEMI group [¥343,800 (¥243,800-343,800)] than in the NSTEMI group [¥220,000 (¥216,800-243,800)] (p < 0.001). Drug eluting stent (85.3% vs. 76.1%, p = 0.029) and aspiration catheter (16.8% vs. 2.3%, p < 0.001) were more frequently used in the STEMI group, whereas rotablator (0.7% vs. 8.3%, p < 0.001) were more frequently used in the NSTEMI group. The multivariate logistic regression analysis revealed that NSTEMI was significantly associated with the high device cost (odds ratio 1.899, 95% confidence interval 1.166-3.093, p = 0.01). In conclusion, the total device cost for PCI was significantly higher in the culprit lesions of NSTEMI than in those of STEMI, whereas the procedure cost was significantly higher in the culprit lesions of STEMI than in those of NSTEMI.
© 2021. Japanese Association of Cardiovascular Intervention and Therapeutics.

Entities:  

Keywords:  Acute myocardial infarction; Cost; Non-ST-segment elevation myocardial infarction; Percutaneous coronary intervention; ST-segment elevation myocardial infarction

Mesh:

Year:  2021        PMID: 33884579     DOI: 10.1007/s12928-021-00778-3

Source DB:  PubMed          Journal:  Cardiovasc Interv Ther        ISSN: 1868-4297


  6 in total

1.  Incidence and Determinants of Complications in Rotational Atherectomy: Insights From the National Clinical Data (J-PCI Registry).

Authors:  Kenichi Sakakura; Taku Inohara; Shun Kohsaka; Tetsuya Amano; Shiro Uemura; Hideki Ishii; Kazushige Kadota; Masato Nakamura; Hiroshi Funayama; Hideo Fujita; Shin-Ichi Momomura
Journal:  Circ Cardiovasc Interv       Date:  2016-11       Impact factor: 6.546

2.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Patrick T O'Gara; Frederick G Kushner; Deborah D Ascheim; Donald E Casey; Mina K Chung; James A de Lemos; Steven M Ettinger; James C Fang; Francis M Fesmire; Barry A Franklin; Christopher B Granger; Harlan M Krumholz; Jane A Linderbaum; David A Morrow; L Kristin Newby; Joseph P Ornato; Narith Ou; Martha J Radford; Jacqueline E Tamis-Holland; Carl L Tommaso; Cynthia M Tracy; Y Joseph Woo; David X Zhao; Jeffrey L Anderson; Alice K Jacobs; Jonathan L Halperin; Nancy M Albert; Ralph G Brindis; Mark A Creager; David DeMets; Robert A Guyton; Judith S Hochman; Richard J Kovacs; Frederick G Kushner; E Magnus Ohman; William G Stevenson; Clyde W Yancy
Journal:  Circulation       Date:  2012-12-17       Impact factor: 29.690

3.  2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Ezra A Amsterdam; Nanette K Wenger; Ralph G Brindis; Donald E Casey; Theodore G Ganiats; David R Holmes; Allan S Jaffe; Hani Jneid; Rosemary F Kelly; Michael C Kontos; Glenn N Levine; Philip R Liebson; Debabrata Mukherjee; Eric D Peterson; Marc S Sabatine; Richard W Smalling; Susan J Zieman
Journal:  Circulation       Date:  2014-09-23       Impact factor: 29.690

4.  The 'Ten Commandments' for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.

Authors:  Jean-Philippe Collet; Holger Thiele
Journal:  Eur Heart J       Date:  2020-10-01       Impact factor: 29.983

5.  Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2.

Authors:  Hirotoshi Watanabe; Takeshi Morimoto; Manabu Ogita; Satoru Suwa; Masahiro Natsuaki; Nobuhiro Suematsu; Yorihiko Koeda; Yoshihiro Morino; Akira Nikaido; Yoshiki Hata; Masayuki Doi; Kiyoshi Hibi; Kazuo Kimura; Shunsuke Yoda; Takeo Kaneko; Koji Nishida; Kazuya Kawai; Koji Yamaguchi; Tetsuzo Wakatsuki; Norimasa Tonoike; Masashi Yamamoto; Shogo Shimizu; Takao Shimohama; Junya Ako; Takeshi Kimura
Journal:  Cardiovasc Interv Ther       Date:  2020-11-12
  6 in total
  2 in total

1.  Association of collateral flow with clinical outcomes in patients with acute myocardial infarction.

Authors:  Shun Ishibashi; Kenichi Sakakura; Satoshi Asada; Yousuke Taniguchi; Hiroyuki Jinnouchi; Takunori Tsukui; Yusuke Watanabe; Kei Yamamoto; Masaru Seguchi; Hiroshi Wada; Hideo Fujita
Journal:  Heart Vessels       Date:  2022-03-15       Impact factor: 1.814

2.  Comparison of medical resource use and total admission cost in patients with acute myocardial infarction between on-hours visit versus off-hours visit.

Authors:  Tsukasa Murakami; Kenichi Sakakura; Hiroyuki Jinnouchi; Yousuke Taniguchi; Takunori Tsukui; Yusuke Watanabe; Kei Yamamoto; Masaru Seguchi; Hiroshi Wada; Hideo Fujita
Journal:  Cardiovasc Interv Ther       Date:  2022-01-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.